Carillon Tower Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Carillon Tower Advisers’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-359,748	Closed	-$22.3M	–	477
2019 Q3	$22.3M	Hold	359,748	–	–	0.16%	230
2019 Q2	$25.6M	Hold	359,748	–	–	0.18%	211
2019 Q1	$28.2M	Hold	359,748	–	–	0.2%	192
2018 Q4	$30.5M	Hold	359,748	–	–	0.26%	154
2018 Q3	$61.6M	Hold	359,748	–	–	0.44%	67
2018 Q2	$46.5M	Hold	359,748	–	–	0.37%	90
2018 Q1	$35.9M	Hold	359,748	–	–	0.28%	118
2017 Q4	$30.7K	Buy	+359,748	New	+$31.2M	0.33%	109

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Carillon Tower Advisers's LGND Position: Q4 2019 in Review

Carillon Tower Advisers sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 359,748 shares — an estimated $22.3M sold.

Carillon Tower Advisers first reported a position in LGND in Q4 2017 and held it in 8 quarters. The position peaked at $61.6M in Q3 2018. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

Carillon Tower Advisers reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Carillon Tower Advisers sold 359,748 Ligand Pharmaceuticals shares in Q4 2019, an estimated $22.3M.
Carillon Tower Advisers first reported a position in Ligand Pharmaceuticals in Q4 2017 and held it in 8 quarters.
Carillon Tower Advisers's Ligand Pharmaceuticals position peaked at $61.6M in Q3 2018.
266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Carillon Tower Advisers's 13F filing for Q4 2019, filed 11 Feb 2020.